NeoGenomics Announces Senior Leadership PromotionsBusiness Wire • 9 days ago
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced two promotions within its senior leadership team, effective immediately. Warren Stone has been promoted...
Share to Feed
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its first quarter 2024 financial results on Tuesday, April 30, 2024. Company...
This is a signal that NEO's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position...
When close to half the companies in the Healthcare industry in the United States have price-to-sales ratios (or "P/S...
Shares of NeoGenomics, Inc. (NASDAQ:NEO Get Free Report) have earned a consensus rating of Moderate Buy from the eleven ratings firms that are covering the stock, Marketbeat...
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, alongside research collaborators, will present key findings from 11 abstracts at the American Association for Cancer...
This price move could indicate a change in the trend, and may be a sell signal for investors...
This price move could indicate a change in the trend, and may be a buy signal for investors...
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today released its 2023 Environmental, Social, and Governance (ESG) Report highlighting progress toward building a more...
Investors eyeing a purchase of NeoGenomics Inc (NEO) stock, but cautious about paying the going market price of 14.90/share, might benefit from considering selling puts among the alternative...